AccessMonitor™

Featured
Brokering the Grand Bargain: Fair Patient Access for Fairly Priced Pharmaceuticals – A New ICER Initiative
US Reimbursement & Value Assessment
Brokering the Grand Bargain: Fair Patient Access for Fairly Priced Pharmaceuticals – A New ICER Initiative
US Reimbursement & Value Assessment
Read more →
US Reimbursement & Value Assessment
Accelerated Approvals Under Scrutiny, Free Pricing Period in Germany Likely Halved and 340B Updates
Int'l Reimbursement & HTA, US Reimbursement & Value Assessment
Accelerated Approvals Under Scrutiny, Free Pricing Period in Germany Likely Halved and 340B Updates
Int'l Reimbursement & HTA, US Reimbursement & Value Assessment
Read more →
Int'l Reimbursement & HTA, US Reimbursement & Value Assessment
International Reference Pricing for Innovative Pharmaceuticals – A Reality Check
US Reimbursement & Value Assessment, Int'l Reimbursement & HTA
International Reference Pricing for Innovative Pharmaceuticals – A Reality Check
US Reimbursement & Value Assessment, Int'l Reimbursement & HTA
Read more →
US Reimbursement & Value Assessment, Int'l Reimbursement & HTA
Evolution of Pricing and Cost Controls for Branded Pharmaceuticals in England – Should the US Industry Take Notice?
Int'l Reimbursement & HTA
Evolution of Pricing and Cost Controls for Branded Pharmaceuticals in England – Should the US Industry Take Notice?
Int'l Reimbursement & HTA
Read more →
Int'l Reimbursement & HTA
Pricing and Reimbursement of Innovative Pharmaceuticals in Germany
Int'l Reimbursement & HTA
Pricing and Reimbursement of Innovative Pharmaceuticals in Germany
Int'l Reimbursement & HTA
Read more →
Int'l Reimbursement & HTA
Recap on 340B Pricing Program - Background, Issues and Recent Development
US Reimbursement & Value Assessment
Recap on 340B Pricing Program - Background, Issues and Recent Development
US Reimbursement & Value Assessment
Read more →
US Reimbursement & Value Assessment
Pricing and Reimbursement of Innovative Drugs in China – A Snapshot of Recent Development
Int'l Reimbursement & HTA
Pricing and Reimbursement of Innovative Drugs in China – A Snapshot of Recent Development
Int'l Reimbursement & HTA
Read more →
Int'l Reimbursement & HTA
Multiple Best Price Reporting Supporting Value-Based Purchasing - CMS Medicaid Drug Rebate Program Update
US Reimbursement & Value Assessment
Multiple Best Price Reporting Supporting Value-Based Purchasing - CMS Medicaid Drug Rebate Program Update
US Reimbursement & Value Assessment
Read more →
US Reimbursement & Value Assessment
The Great Rebate Debate – The Anti-Rebate Rule for Medicare Part D
US Reimbursement & Value Assessment
The Great Rebate Debate – The Anti-Rebate Rule for Medicare Part D
US Reimbursement & Value Assessment
Read more →
US Reimbursement & Value Assessment
Medicare Part B and Most-Favored Nation Model Explained
US Reimbursement & Value Assessment
Medicare Part B and Most-Favored Nation Model Explained
US Reimbursement & Value Assessment
Read more →
US Reimbursement & Value Assessment

AdvisorViews™

Featured
Brett McQueen
Preparing for a Review by the Institute of Clinical and Economic Review
Brett McQueen
Read more →
Brett McQueen
Steve Duff
Advice on ICER Review
Steve Duff
Read more →
Steve Duff
Steve Duff
Advice on Integrating Economic Evaluation into Clinical Development Programs
Steve Duff
Read more →
Steve Duff
Steve Duff
The Role of Economic Evaluation in the Pricing and Reimbursement of Medicines in the United States
Steve Duff
Read more →
Steve Duff
Mike Chambers
Planning for successful submissions to health technology assessment agencies
Mike Chambers
Read more →
Mike Chambers